Aiyede Mimieveshiofuo, Lim Xin Yi, Russell Ash A M, Patel Rahul P, Gueven Nuri, Howells David W, Bye Nicole
School of Pharmacy and Pharmacology, University of Tasmania, Hobart, Tasmania, Australia.
Herbal Medicine Research Centre, Institute for Medical Research, Ministry of Health, Kuala Lumpur, Malaysia.
J Neurotrauma. 2023 Jan;40(1-2):4-21. doi: 10.1089/neu.2022.0020. Epub 2022 Sep 12.
The identification of effective pharmacotherapies for traumatic brain injury (TBI) remains a major challenge. Treatment with heparin and its derivatives is associated with neuroprotective effects after experimental TBI; however, the optimal dosage and method of administration, modes of action, and effects on hemorrhage remain unclear. Therefore, this review aimed to systematically evaluate, analyze, and summarize the available literature on the use of heparin and low molecular weight heparins (LMWHs) as treatment options for experimental TBI. We searched two online databases (PubMed and ISI Web of Science) to identify relevant studies. Data pertaining to TBI paradigm, animal subjects, drug administration, and all pathological and behavior outcomes were extracted. Eleven studies met our pre-specified inclusion criteria, and for outcomes with sufficient numbers, data from seven publications were analyzed in a weighted mean difference meta-analysis using a random-effects model. Study quality and risk of bias were also determined. Meta-analysis revealed that heparin and its derivatives decreased brain edema, leukocyte rolling, and vascular permeability, and improved neurological function. Further, treatment did not aggravate hemorrhage. These findings must be interpreted with caution, however, because they were determined from a limited number of studies with substantial heterogeneity. Also, overall study quality was low based on absences of data reporting, and potential publication bias was identified. Importantly, we found that there are insufficient data to evaluate the variables we had hoped to investigate. The beneficial effects of heparin and LMWHs, however, suggest that further pre-clinical studies are warranted.
确定有效的创伤性脑损伤(TBI)药物治疗方法仍然是一项重大挑战。在实验性TBI后,使用肝素及其衍生物进行治疗具有神经保护作用;然而,最佳剂量和给药方法、作用方式以及对出血的影响仍不明确。因此,本综述旨在系统评价、分析和总结关于使用肝素和低分子量肝素(LMWHs)作为实验性TBI治疗选择的现有文献。我们检索了两个在线数据库(PubMed和ISI科学网)以识别相关研究。提取了与TBI模型、动物受试者、药物给药以及所有病理和行为结果相关的数据。11项研究符合我们预先设定的纳入标准,对于有足够数量数据的结果,使用随机效应模型对7篇出版物的数据进行加权平均差元分析。还确定了研究质量和偏倚风险。元分析显示,肝素及其衍生物可减轻脑水肿、白细胞滚动和血管通透性,并改善神经功能。此外,治疗并未加重出血。然而,这些发现必须谨慎解读,因为它们是基于数量有限且异质性较大的研究得出的。此外,由于缺乏数据报告,总体研究质量较低,并且发现了潜在的发表偏倚。重要的是,我们发现没有足够的数据来评估我们希望研究的变量。然而,肝素和LMWHs的有益作用表明有必要进行进一步的临床前研究。